Dr. Agarwal's Health Care Posts Stellar Q3 Growth, PAT Surges 55%

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorIshaan Verma|Published at:
Dr. Agarwal's Health Care Posts Stellar Q3 Growth, PAT Surges 55%
Overview

Dr. Agarwal's Health Care Limited reported robust Q3 FY26 results, with revenue from operations climbing 23% YoY to Rs. 530 Cr. PAT surged 55% YoY to Rs. 44 Cr, driven by a 21.3% rise in EBITDA to Rs. 155 Cr and improved margins. The company commissioned 14 new facilities, expanding its network to 253, and saw significant growth in high-end surgeries. Management expressed confidence in meeting annual guidance, with plans for further aggressive expansion.

Dr. Agarwal's Health Care: Robust Expansion Fuels Stellar Q3 Performance

Dr. Agarwal's Health Care Limited showcased impressive financial results for Q3 FY26, with revenue from operations climbing 23% year-on-year to Rs. 530 Cr. Profit After Tax (PAT) witnessed a significant surge of 55% YoY, reaching Rs. 44 Cr, supported by a 21.3% increase in EBITDA to Rs. 155 Cr. The company's aggressive network expansion strategy continued, adding 14 new Greenfield facilities in the quarter, extending its total network to 253. For the nine months ended December 2025, the company posted a total income of Rs. 1,548 Cr (+20.8% YoY) and PAT grew by a substantial 74.3% YoY to Rs. 118 Cr.

Growth was further fueled by a substantial increase in high-end surgical procedures. Notably, robotic cataract surgeries (Femto cataract) saw an 83% YoY jump, while high-end cataract surgeries grew by 43.5%. Lenticular (SMILE) surgeries grew 17.7% YoY, and retinal surgeries increased by 23.2% YoY. This performance underscores the company's successful strategy in expanding its reach and enhancing its service offerings. Daily patient walk-ins also increased by 25% year-on-year.

Financial Deep Dive

  • The Numbers:
    • 9MFY26 Total Income: Rs. 1,548 Cr (+20.8% YoY)
    • 9MFY26 Revenue from Operations: Rs. 1,516 Cr (+21.2% YoY)
    • 9MFY26 EBITDA: Rs. 440 Cr (+23.6% YoY), Margin: 28.4% (+64 bps YoY)
    • 9MFY26 PAT: Rs. 118 Cr (+74.3% YoY), Margin: 7.6% (+234 bps YoY)
    • Q3FY26 Revenue from Operations: Rs. 530 Cr (+23% YoY)
    • Q3FY26 Total Income: Rs. 540 Cr
    • Q3FY26 EBITDA: Rs. 155 Cr (+21.3% YoY), Margin: 28.4%
    • Q3FY26 PAT: Rs. 44 Cr (+55% YoY), Margin: 8.1% (+171 bps YoY)
  • The Quality: Margins are expanding both at EBITDA and PAT levels YoY. PAT growth significantly outpaces revenue growth, indicating operating leverage and improved profitability. CAPEX YTD of Rs. 275 Cr highlights investment in growth infrastructure. Repayment of Rs. 95 Cr in loans from IPO proceeds is a positive step towards deleveraging and reducing finance costs. Greenfield losses are contained and cohort profitability is a good sign.
  • The Grill: Management guidance is met, and confidence is expressed for the fiscal year. Focus is on operational efficiency and disciplined execution. No specific grilling points were mentioned in the provided text.

Risks & Outlook

  • Merger Integration: The merger process is ongoing, with completion expected by Q3/Q4 2027, introducing execution and timeline risks.
  • International Expansion: Entry into the Ethiopian market is in the feasibility study phase, carrying inherent risks and requiring substantial investment.
  • Execution Risk: Sustaining the aggressive pace of opening 55-60 new facilities annually requires significant operational and management bandwidth.
  • Outlook: Management is confident in meeting guidance. The focus remains on operational efficiency, disciplined expansion, and technology investments. Investors should watch the merger progress and the pace of new facility ramp-ups. The company is also exploring organic entry into the Ethiopian market.

Impact (8/10): The strong financial results, coupled with aggressive expansion and focus on high-margin, advanced procedures, position Dr. Agarwal's Health Care favorably within the Indian healthcare sector. This performance is likely to attract investor interest and could drive positive stock movement.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.